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The successful treatment of cancer using chemotherapy requires
two conditions to be met. For each patient, and their tumour,
the correct drug(s) must be selected and the right dose(s) must
be administered. Pre-clinical and clinical research in cancer
chemotherapy is currently focused on satisfying the ﬁrst condition,
mainly through the search for new drugs with greater activity and
tumour selectivity. The generic approach being taken is to identify
targets related to the molecular or cellular pathology of cancer,
followed by the development of agents which interact with these
targets and produce the required change in tumour cell biology
or host-tumour interactions. Target-based drug development is
beginning to bare fruit and there is widespread optimism that a
new generation of more selective and more active drugs will soon
be with us.
The paper by Gurney in the current issue (Gurney, 2002)
addresses the second of the two conditions that must be met for
successful treatment, namely, the selection of the correct drug dose
for each patient. The convention for many decades has been to use
body surface area to calculate drug doses, the rationale being that
drug clearance varies as a function of this parameter reﬂecting rela-
tionships between surface area and metabolic rate, blood ﬂow,
renal function, etc. Thus, patients receive a ﬁxed number of, for
example, mg per m
2, and a number of nomograms and equations
exist for calculating surface area from weight and height. The accu-
racy of these methods of calculating surface area has been the
subject of much debate, and this calculation alone introduces inac-
curacies. On top of these inaccuracies, and of greater importance,
there are signiﬁcant inter-patient, and to a lesser extent intra-indi-
vidual, differences in drug clearance that are not related to surface
area. Gurney lists a number of speciﬁc reasons for surface area-
independent variations in drug clearance, and these include vari-
ability in the activity of drug metabolising enzymes and transpor-
ters for genetic reasons, pharmacokinetic interactions due to
concomitant medication, and impaired organ function due to
either disease or prior therapy. Given all these very real issues,
and the compelling case made by Gurney, it is amazing that the
habit of using surface area to adjust doses has persisted for so long.
A major reason for using surface area in the ﬁrst instance stems
from the early data of Freireich and colleagues (Freireich et al,
1966), who showed that maximum tolerated doses of cytotoxic
drugs where often the same in different species, ranging from mice
to humans, when doses were scaled according to surface area.
Toxic doses were less consistent when body weight was used to
normalise doses. The consistency of toxic doses across species when
normalised to body surface area reﬂects the general relationship
between surface area and a number of physiological processes
which together determine drug clearance, as alluded to above.
There is of course no doubt that drug doses in children, particu-
larly infants, must be reduced relative to doses in adults.
However, in an adult population there is really no reason to use
surface area in determining doses, unless surface area does correlate
with clearance across the range of body sizes seen in the target
adult population.
Table 4 in Gurney’s paper provides 12 commonsense ‘rules’ that
every physician should have in mind when prescribing doses of
cytotoxic therapy, and the role of pharmacists and nurses in this
process is similarly important. Taking account of these issues
should ensure that a safe, but not sub-therapeutic, dose is
prescribed on the ﬁrst occasion a patient is treated. Subsequently,
biological endpoints (rule 11) should be used to adjust doses for
each individual patient, as previously advocated by the author
(Gurney, 1996), to ensure that over the course of therapy each
individual patient is given the best chance of therapeutic beneﬁt
whilst being exposed to manageable and not excessive levels of
toxicity. In the case of cytotoxic drugs, the biological endpoint
most frequently used as a surrogate for antiproliferative activity
against tumour cells is damage to diving normal tissues, and
myelosuppression and mucosistis are frequently used to adjust
doses. Unfortunately, as noted by Gurney, these adjustments rarely
include dose escalation in patients in whom no toxicity is observed,
with the result that such paitents are likely to be under treated.
Whilst the approach proposed by Gurney is eminently sensible
for cytotoxic drugs, which have a narrow therapeutic index and
a sensitive normal tissue where toxicity is related to the mechanism
of drug action and easy to measure, the same may not be true for
the new generation of cancer drugs. For more selective targeted
drugs, the therapeutic index may be wider and ﬁxed dosing, i.e.
not adjusted on the basis of surface area, has already been success-
fully used in a number of trials, particularly where the drug is
given orally. The real challenge is to ﬁnd ways of monitoring the
biological activity of these new treatments in patients to ensure that
individuals are given potentially active doses, and non-invasive
pharmacodynamic techniques (e.g. functional imaging) may have
a role in this respect.
An alternative to measuring biological endpoints for dose opti-
misation is to use pharmacokinetic data, often referred to as Received 10 February 2002; accepted 11 February 2002
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drug for which target plasma concentrations have been identiﬁed,
and thus it applies to both cytotoxic and non-cytotoxic therapies.
Evans and colleagues have shown that in childhood acute lympho-
blastic leukaemia dose adjustment on the basis of pharmacokinetic
data can indeed result in improved outcome results (Evans et al,
1998), although the logistical challenges involved in delivering
pharmacokinetically-guided dosing can be substantial.
Gurney’s paper comes as a timely reminder that for maximum
efﬁcacy dose can be as important as selecting the right drug, and
that optimum doses for individual patients will vary widely. The
approach advocated by Gurney, namely to take all possible pre-
treatment and post-treatment clinical and pharmacological data
into account in prescribing, makes eminent sense. In particular,
reliance upon surface area as the primary determinant of dose
should be seriously questioned. For new agents, Phase II and Phase
III trials in adults should avoid using surface area-normalised
dosing. An exception would be when pharmacokinetic data show
that drug clearance is signiﬁcantly related to body surface area,
and that an alternative simple physiological parameter, e.g. renal
function, is not more signiﬁcantly related. For established drugs,
a widespread move away from surface area based dosing is likely
to need randomised trials to conﬁrm that so doing does not impair
efﬁcacy or result in increased toxicity. Unfortunately, to be sure
that the incidence of rare by serious toxicities is not increased, such
trials would need to be large and realistically they are unlikely to be
performed. Nevertheless, for standard patient care, the rules
deﬁned by Gurney are an excellent step in the right direction for
physicians, pharmacists and nurses who are prepared to get to
grips with the pharmacology of the drugs they use.
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